PLTR News: Palantir Technologies falls as the stock sheds 12% during July
Premium|Take advantage of 50% OFF on your first month.
Start your subscription and get access to all our original articles.
You have reached your limit of 5 free articles for this month.
Get all exclusive analysis, access our analysis and get Gold and signals alerts
Elevate your trading Journey.
UPGRADE- NYSE:PLTR declined to close the week as the stock fell by 2.12%.
- Palantir’s involvement in the UK government has its share of critics.
- Lilium is set to merge with its SPAC in the third quarter of 2021.
NYSE:PLTR closed out the month of July in the red, as the popular data analytics company declined by a total of 12% during the month. On Friday, shares of Palantir fell by 2.12% to close the trading session at $21.71. The markets were dragged down by the eCommerce giant Amazon (NASDAQ:AMZN) which tumbled 7.6% as the company missed revenue estimates for the second quarter. All three major indices closed the day in the red, although the S&P 500 managed to eke out its sixth straight positive month. Palantir was not able to hold its 8 day exponential moving average, and sees a declining RSI, which is generally an indication that the general trend is still bearish.
Stay up to speed with hot stocks' news!
Palantir is still working on its reputation in the court of public opinion, and it’s recent contracts with the UK government have not done much to improve this. NHS employees have openly criticized Palantir’s Foundry platform which allegedly impedes their ability to access certain datasets. After being awarded nearly £100 million over the years, UK citizens have spoken out against the company, causing the government to re-evaluate further contract extensions.
PLTR stock forecast
One of Palantir’s recent SPAC PIPE investments is Lilium, is a vertical take off, or eVTOL company based out of Germany. The company is merging with Qell Acquisiiton Corp (NASDAQ:QELL) and announced it would be completing the merger at some time in the third quarter of 2021. Palantir is an early investor in Lilium, alongside Chinese tech conglomerate Tencent, and Lilium has already been approved to begin using Palantir’s Foundry platform for its data analytics.
- NYSE:PLTR declined to close the week as the stock fell by 2.12%.
- Palantir’s involvement in the UK government has its share of critics.
- Lilium is set to merge with its SPAC in the third quarter of 2021.
NYSE:PLTR closed out the month of July in the red, as the popular data analytics company declined by a total of 12% during the month. On Friday, shares of Palantir fell by 2.12% to close the trading session at $21.71. The markets were dragged down by the eCommerce giant Amazon (NASDAQ:AMZN) which tumbled 7.6% as the company missed revenue estimates for the second quarter. All three major indices closed the day in the red, although the S&P 500 managed to eke out its sixth straight positive month. Palantir was not able to hold its 8 day exponential moving average, and sees a declining RSI, which is generally an indication that the general trend is still bearish.
Stay up to speed with hot stocks' news!
Palantir is still working on its reputation in the court of public opinion, and it’s recent contracts with the UK government have not done much to improve this. NHS employees have openly criticized Palantir’s Foundry platform which allegedly impedes their ability to access certain datasets. After being awarded nearly £100 million over the years, UK citizens have spoken out against the company, causing the government to re-evaluate further contract extensions.
PLTR stock forecast
One of Palantir’s recent SPAC PIPE investments is Lilium, is a vertical take off, or eVTOL company based out of Germany. The company is merging with Qell Acquisiiton Corp (NASDAQ:QELL) and announced it would be completing the merger at some time in the third quarter of 2021. Palantir is an early investor in Lilium, alongside Chinese tech conglomerate Tencent, and Lilium has already been approved to begin using Palantir’s Foundry platform for its data analytics.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.